Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.

TechTarget Inc (TTGT)

3,65

0,00

(0,00%)

Fermé 16 Juin 10:00PM

0,00

0,00

(0,00%)

Après les heures de négociation: -

TechTarget Inc ([symbol]) Options

TTGT Flux des options

Achats

Strike	Achat	Vente	Dernier Prix	Point Médian	Var	Var %	Volume	INT OUVERT	Dernière Trans
2,50	0,95	1,70	1,15	1,325	0,00	0,00 %	0	1	-
5,00	0,00	0,90	0,11	0,11	0,00	0,00 %	0	167	-
7,50	0,00	1,55	0,35	0,35	0,00	0,00 %	0	52	-
10,00	0,00	1,55	0,45	0,45	0,00	0,00 %	0	10	-

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Ventes

Strike	Achat	Vente	Dernier Prix	Point Médian	Var	Var %	Volume	INT OUVERT	Dernière Trans
2,50	0,00	0,05	0,00	0,00	0,00	0,00 %	0	0	-
5,00	1,00	1,75	0,00	1,375	0,00	0,00 %	0	0	-
7,50	3,20	4,40	2,64	3,80	0,00	0,00 %	0	0	-
10,00	5,60	7,10	0,00	6,35	0,00	0,00 %	0	0	-

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
SHOEShoe Station Group Inc	US$ 16,85 (16 750,00%)	590,42k
CASTFreeCast Inc	US$ 3,73 (140,65%)	158,15M
CUPRCuprina Holdings Cayman Ltd	US$ 8,48 (113,60%)	48,56M
VSMEVS Media Holdings Ltd	US$ 3,25 (92,31%)	64,72M
PRFXPRF Technologies Ltd	US$ 2,4801 (82,36%)	47,33M
ELTXElicio Therapeutics Inc	US$ 4,07 (-72,59%)	8,46M
MEHAFunctional Brands Inc	US$ 0,01845 (-55,43%)	77,56M
CNTXContext Therapeutics Inc	US$ 0,6794 (-51,12%)	20,59M
NMRANeumora Therapeutics Inc	US$ 0,9177 (-48,44%)	17,74M
SNBRSleep Number Corporation	US$ 0,2202 (-43,57%)	17,1M
ADTXAditxt Inc	US$ 0,013 (2,36%)	827,76M
PAVSParanovus Entertainment Technology Ltd	US$ 0,177 (-14,90%)	671,36M
SPCXSpace Exploration Technologies Corporation	US$ 192,50 (19,60%)	256,78M
WOKWORK Medical Technology Group Ltd	US$ 0,0856 (13,68%)	199,07M
GDCGD Culture Group Ltd	US$ 0,1034 (4,44%)	190,17M

US Market News

US Market News il y a 8 minutes

Unilever Scales Digital Twins Across Global Manufacturing Network with AccentureJune 16, 2026 2:59 AM
Business WireUnilever (LON: ULVR) is partnering with Accenture (NYSE: ACN) to scale the use of AI-enabled digital twins across its global manufacturing network

CelestialSage6

CelestialSage6 il y a 10 minutes

You can't refute it. Yes, I understand your level well.

biotechinvestor1

biotechinvestor1 il y a 16 minutes

Total nonsense! I have no interest in educating you.

Nemesis18

Nemesis18 il y a 17 minutes

She'll probably move to somewhere without any extradition treaty once the plug is finally pulled on this 'cancer vaccine' scam.?

price_and_volume

price_and_volume il y a 20 minutes

Gonna have to bump the A/S then...
He said recently that they are looking at another acquisition...and he will dilute with shares to get it. Agreed - I posted the same, "where's the finance coming from for acquisitions?"...

Supposed 400MM shares going to $GTVH (believe it when

StockItOut

StockItOut il y a 20 minutes

WKSP Weekly chart: https://schrts.co/IIIuZpgy

CelestialSage6

CelestialSage6 il y a 21 minutes

I understand that Halozyme has not signed any exclusive agreements regarding treatments or indications related to Dupixent, so why is Sanofi collaborating with Alteogen?

Also, Halozyme's mdase patent is being invalidated due to Merck. Alteogen's technology is more advanced than Halozy

Wolf-man jack

Wolf-man jack il y a 23 minutes

WQLF SAYS: Have Mercy WQLF ahoooooo

Q: Why hasn't CV SCIENCES been accepted in the CMS Medicare Pilot Program?

Ai Generated:

C V Sciences has not been "accepted" into the CMS Medicare Pilot Program because the pilot is a provider-led incentive, not a

price_and_volume

price_and_volume il y a 24 minutes

What reasonable expectation is there of PPS responding?
whether management can successfully execute on the vision they have laid out. Nobody cares about "the company" or "the management" or "their vision" or your two-bit-MBA-tutorials-in-a-post.

Enough of all that garbage.

mrwrn2010

mrwrn2010 il y a 27 minutes

Disagree. The outcome of OxyContin litigation was unknown 9 months to a year ago. You can guess at a variety of outcomes, sure, but it’s not certain. Same thing with human trials - we don’t have positive trial results for anything in the pipeline until we have them. What passes in vitro may not pass

PEACHMAN

PEACHMAN il y a 29 minutes

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177680761

IFUS STRONG

price_and_volume

price_and_volume il y a 30 minutes

I get that, but that's not what I asked.

I'm not bullying you or accusing you of pumping.

You repeatedly point out what you consider to be nefarious shenanigans, so I asked: PPS hasn't effectively changed in THREE YEARS , other than a few short days 1 year ago this wee

Homework.Investwell

Homework.Investwell il y a 36 minutes

2017 Northwest Biotherapeutics, Inc.
4800 Montgomery Lane, Suite 800

Suite 800 is empty....🤔

Linda lives in Missouri now but headquarters could be moved anywhere...or will they need it?

I think we're going to find out by the end of the sum

Mdk1

Mdk1 il y a 39 minutes

Why this paper is highly interesting for Lightwave Logic (GROK)
This is a top-scored paper that strongly validates Lightwave Logic’s Perkinamine™ chromophore series 3 as a leading electro-optic material for next-generation datacenter optics.

Key Reasons Why It Matters:

janice shell

janice shell il y a 45 minutes

Now that's a real head-scratcher! But shorts have to be smart, so I'd say torso and head.

gitreal

gitreal il y a 48 minutes

Anyone with half a Brian can see this company is being crazy shorted!

Which half? Torso and head?

HyGro

HyGro il y a 52 minutes

NWBO could file an FDA application anytime but they haven't and have shown no intent to do so. Instead they are just burning more shareholder cash and if approved, will lose money on every dose because NICE will hammer the reimbursement down below Advent's costs. NWBO will lose money and collaps

US Market News

US Market News il y a 53 minutes

TotalEnergies SE: Disclosure of Transactions in Own SharesJune 16, 2026 2:00 AM
Business Wire Regulatory News In accordance with the authorizations given by the shareholders’ general meeting on May 29, 2026, to trade on its shares and pursuant to applicable law on share

HyGro

HyGro il y a 55 minutes

Sorry, not enough. NWBO won't make any profit selling in the UK. NICE hates personalized oncology treatments and won't pay enough for NWBO to make a profit.
That's what counts. And NWBO will go under or just become Advent Contract Manufacturer. They have no cash or credit to fund any sub

biotechinvestor1

biotechinvestor1 il y a 57 minutes

Don’t start spazzing again, Alteogen circus clown. The Sanofi news is old.
Once Merck settles/licenses from Halozyme, Sanofi and all others will follow.
Your Alteogen stole IP from Halozyme and will pay a price for it. You can count on it.
The companies who have signed with Alte

Steady_T

Steady_T il y a 58 minutes

Your theory will be put to the test after UK approval. I give it 6 months as a guess.

HyGro

HyGro il y a 58 minutes

What's true is NWBO won't file with the FDA for approval in the U.S. Hasn't done it for years when it could have done it. They know FDA won't accept their P3 trial. How many years are you going to wait to find out???

HyGro

HyGro il y a 59 minutes

What's True is NWBO won't file with the FDA for approval in the U.S. Hasn't done it for years when it could have done it. They know FDA won't accept their P3 trial. How long are you going to wait to find out???

Mdk1

Mdk1 il y a 1 heure

Google Scholar alert - new article: "A Comparison of Plasmonic Modulator Structures in the O- and C-Band for the 400G/Lane IM/DD Era"
>>> " In ALL cases, the same electro-optic organic material, Lightwave Logic’s PerkinamineTM
chromophore series 3, was used " !
https://ieeexplor

CelestialSage6

CelestialSage6 il y a 1 heure

Stop talking nonsense. Sanofi is conducting clinical trials using Alteogen's technology; what are your thoughts on this? Did you sense a crisis for Halozyme?

Delayed Upgrade Clock

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

ADVFN

Vous avez déjà un compte? Connexion

Vous n'avez pas de compte ? Inscription

En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.